Sugi Predict

Sugi Predict / Targets / SMO

SMO

Protein smoothened · Q99835 · SMO on Sugi Atlas →

49,256 patent compounds predicted against SMO, 25,141 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Hydrochloric Acid Hydrochloric Acid (SCHEMBL241989) 0.68 18/20
SCHEMBL242762 SCHEMBL242762 0.61 18/20
SCHEMBL315678 SCHEMBL315678 0.53 18/20
Sulfuric Acid Sulfuric Acid (SCHEMBL242761) 0.65 17/20
SCHEMBL240700 SCHEMBL240700 0.62 17/20
SCHEMBL242583 SCHEMBL242583 0.69 16/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL243778) 0.52 15/20
SCHEMBL162087 SCHEMBL162087 0.64 14/20
SCHEMBL239706 SCHEMBL239706 0.58 14/20
Bromide Bromide (SCHEMBL243397) 0.57 14/20
SCHEMBL243394 SCHEMBL243394 0.55 14/20
SCHEMBL245081 SCHEMBL245081 0.53 14/20
Bromide Bromide (SCHEMBL242629) 0.52 14/20
SCHEMBL244089 SCHEMBL244089 0.50 14/20
SCHEMBL243666 SCHEMBL243666 0.55 13/20
SCHEMBL244319 SCHEMBL244319 0.54 13/20
SCHEMBL162840 SCHEMBL162840 0.54 13/20
SCHEMBL243913 SCHEMBL243913 0.53 13/20
SCHEMBL242777 SCHEMBL242777 0.55 12/20
SCHEMBL243749 SCHEMBL243749 0.56 11/20

Clinical trials — most relevant to SMO by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 PHASE4COMPLETED
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer PHASE2COMPLETED
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome PHASE2WITHDRAWN
Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression PHASE2COMPLETED
Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In Men With Castration-Resistant Prostate Cancer (CRPC) PHASE1/PHASE2WITHDRAWN
Vismodegib for Treatment of Basal Cell Carcinoma PHASE2COMPLETED
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Study Evaluating the Efficacy of Oral Vismodegib in Various Histologic Subtypes PHASE2COMPLETED
Trial of Patidegib Gel 2%, 4%, and Vehicle to Decrease the Number of Surgically Eligible Basal Cell Carcinomas in Gorlin Syndrome Patients PHASE2COMPLETED
Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas PHASE2COMPLETED
Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis PHASE2COMPLETED
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery PHASE2COMPLETED
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma PHASE2COMPLETED
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer PHASE2RECRUITING
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients PHASE1COMPLETED
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC) PHASE1COMPLETED
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment PHASE1COMPLETED
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma PHASE1COMPLETED
A Study Of PF-04449913 Administered Alone In Select Solid Tumors PHASE1COMPLETED
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors PHASE1COMPLETED
Novel Molecular Targets and Innovative Therapeutic Perspective in Medulloblastoma EARLY_PHASE1RECRUITING
Topical Itraconazole in Treating Patients With Basal Cell Cancer EARLY_PHASE1COMPLETED
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer EARLY_PHASE1UNKNOWN
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin. nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SMO binder may also engage these)

ProteinNameSimilarity
P97698 — 0.999 P97698 →
P56726 — 0.998 P56726 →
O42224 — 0.991 O42224 →
E1BBQ2 — 0.975 E1BBQ2 →
P97260 — 0.974 P97260 →
A6QM06 — 0.974 A6QM06 →
A2RRU4 — 0.972 A2RRU4 →
Q6GQT6 — 0.972 Q6GQT6 →
Q12770 — 0.971 Q12770 →
Q5MNU5 — 0.971 Q5MNU5 →
Q5GH73 — 0.971 Q5GH73 →
Q9R283 — 0.971 Q9R283 →
Q5RH73 — 0.970 Q5RH73 →
D4A6L0 — 0.970 D4A6L0 →
Q5GH57 — 0.968 Q5GH57 →
Q5T848 — 0.967 Q5T848 →
E9Q6C8 — 0.967 E9Q6C8 →
Q9NRU3 — 0.966 Q9NRU3 →
Q9EPI0 — 0.966 Q9EPI0 →
Q8C419 — 0.966 Q8C419 →
Q9R244 — 0.965 Q9R244 →
Q8C4U2 — 0.965 Q8C4U2 →
B1ATG9 — 0.964 B1ATG9 →
Q5QQ51 — 0.964 Q5QQ51 →
Q6ZMZ0 — 0.963 Q6ZMZ0 →
Q9H1B5 — 0.963 Q9H1B5 →
Q5QQ50 — 0.963 Q5QQ50 →
A2SXS5 — 0.962 A2SXS5 →
Q9CZ52 — 0.962 Q9CZ52 →
Q4GZT3 — 0.961 Q4GZT3 →